REPAGLINIDE

Repaglinide Adverse Events Reported to the FDA Over Time

How are Repaglinide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Repaglinide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Repaglinide is flagged as the suspect drug causing the adverse event.

Most Common Repaglinide Adverse Events Reported to the FDA

What are the most common Repaglinide adverse events reported to the FDA?

Hypoglycaemia	81 (5.77%)
Renal Failure	26 (1.85%)
Renal Failure Acute	25 (1.78%)
Diarrhoea	24 (1.71%)
Drug Interaction	22 (1.57%)
Dizziness	21 (1.5%)
Lactic Acidosis	19 (1.35%)
Thrombocytopenia	19 (1.35%)
Dehydration	18 (1.28%)
Hypoglycaemic Coma	18 (1.28%)
Hypotension	18 (1.28%)
	Show More
Anaemia	17 (1.21%)
Eosinophilia	14 (1%)
Nephropathy	13 (.93%)
Confusional State	12 (.85%)
Somnolence	12 (.85%)
Hepatic Cirrhosis	11 (.78%)
Leukopenia	11 (.78%)
Rhabdomyolysis	11 (.78%)
Vomiting	11 (.78%)
Alanine Aminotransferase Increased	10 (.71%)
Dyspnoea	10 (.71%)
Pruritus	10 (.71%)
Rash Maculo-papular	10 (.71%)
Renal Impairment	10 (.71%)
Tubulointerstitial Nephritis	10 (.71%)
Aspartate Aminotransferase Increase...	9 (.64%)
Fatigue	9 (.64%)
Hepatitis	9 (.64%)
Leukocytoclastic Vasculitis	9 (.64%)
Psychomotor Hyperactivity	9 (.64%)
Blood Creatinine Increased	8 (.57%)
Condition Aggravated	8 (.57%)
Dysarthria	8 (.57%)
Jaundice	8 (.57%)
Rash Erythematous	8 (.57%)
Asthenia	7 (.5%)
Colitis	7 (.5%)
Cytolytic Hepatitis	7 (.5%)
Depressed Level Of Consciousness	7 (.5%)
Epistaxis	7 (.5%)
Gait Disturbance	7 (.5%)
Gamma-glutamyltransferase Increased	7 (.5%)
Haematoma	7 (.5%)
Hypothermia	7 (.5%)
Injection Site Haemorrhage	7 (.5%)
Intentional Overdose	7 (.5%)
Intestinal Obstruction	7 (.5%)
Myoclonus	7 (.5%)
Oedema	7 (.5%)
Pancreatic Enzymes Increased	7 (.5%)
Proctocolitis	7 (.5%)
Rales	7 (.5%)
Sopor	7 (.5%)
Anion Gap Increased	6 (.43%)
Atrial Fibrillation	6 (.43%)
Death	6 (.43%)
Disturbance In Attention	6 (.43%)
Encephalopathy	6 (.43%)
Hyperglycaemia	6 (.43%)
Hyperkalaemia	6 (.43%)
Hyperuricaemia	6 (.43%)
Inflammation	6 (.43%)
Malaise	6 (.43%)
Neurotoxicity	6 (.43%)
Pancreatitis Acute	6 (.43%)
Rash	6 (.43%)
Suicide Attempt	6 (.43%)
Vascular Purpura	6 (.43%)
Acute Coronary Syndrome	5 (.36%)
Aphasia	5 (.36%)
Blood Glucose Increased	5 (.36%)
Cardiac Failure	5 (.36%)
Cardiogenic Shock	5 (.36%)
Drug Rash With Eosinophilia And Sys...	5 (.36%)
Haematuria	5 (.36%)
Hepatic Function Abnormal	5 (.36%)
Idiopathic Urticaria	5 (.36%)
Interstitial Lung Disease	5 (.36%)
Myocardial Ischaemia	5 (.36%)
Purpura	5 (.36%)
Unresponsive To Stimuli	5 (.36%)
Acute Generalised Exanthematous Pus...	4 (.28%)
Agranulocytosis	4 (.28%)
Anaemia Haemolytic Autoimmune	4 (.28%)
Angina Pectoris	4 (.28%)
Bladder Cancer	4 (.28%)
Cardiac Arrest	4 (.28%)
Completed Suicide	4 (.28%)
Drug Intolerance	4 (.28%)
Fall	4 (.28%)
Haemodialysis	4 (.28%)
Haemoglobin Decreased	4 (.28%)
Haemolytic Anaemia	4 (.28%)
Heart Rate Decreased	4 (.28%)
Hemiparesis	4 (.28%)
Hepatic Steatosis	4 (.28%)
Hepatitis Acute	4 (.28%)
Hydrocephalus	4 (.28%)
Hyperthermia	4 (.28%)
Inappropriate Schedule Of Drug Admi...	4 (.28%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Repaglinide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Repaglinide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Repaglinide

What are the most common Repaglinide adverse events reported to the FDA?

Neurological	113 (8.05%)
Glucose Metabolism Disorders	91 (6.48%)
Hepatic And Hepatobiliary	66 (4.7%)
Renal Disorders	66 (4.7%)
Epidermal And Dermal Conditions	64 (4.56%)
Hepatobiliary	35 (2.49%)
White Blood Cell	34 (2.42%)
Respiratory	33 (2.35%)
Therapeutic And Nontherapeutic Effe...	33 (2.35%)
Medication Errors	27 (1.92%)
Electrolyte And Fluid Balance Condi...	26 (1.85%)
	Show More
Hematology Investigations	25 (1.78%)
Gastrointestinal Motility And Defec...	24 (1.71%)
Nephropathies	24 (1.71%)
Acid-base	23 (1.64%)
Anemias Nonhemolytic And Marrow Dep...	22 (1.57%)
Movement Disorders	22 (1.57%)
Platelet	22 (1.57%)
Decreased And Nonspecific Blood Pre...	21 (1.5%)
Muscle	21 (1.5%)
Gastrointestinal Signs	20 (1.42%)
Infections - Pathogen Unspecified	20 (1.42%)
Metabolic, Nutritional And Blood Ga...	20 (1.42%)
Skin Vascular Abnormalities	20 (1.42%)
Coronary Artery	18 (1.28%)
Gastrointestinal Inflammatory Condi...	16 (1.14%)
Lower Respiratory Tract Disorders	15 (1.07%)
Renal And Urinary Tract Investigati...	15 (1.07%)
Cardiac Arrhythmias	14 (1%)
Body Temperature Conditions	13 (.93%)
Deliria	12 (.85%)
Suicidal And Self-injurious Behavio...	12 (.85%)
Angiedema And Urticaria	11 (.78%)
Heart Failures	11 (.78%)
Cardiac And Vascular Investigations	10 (.71%)
Encephalopathies	10 (.71%)
Physical Examination Topics	10 (.71%)
Renal And Urinary Tract Neoplasms M...	10 (.71%)
Urinary Tract Signs	10 (.71%)
Exocrine Pancreas Conditions	9 (.64%)
Sleep Disorders	9 (.64%)
Vascular Hemorrhagic	9 (.64%)
Fatal Outcomes	8 (.57%)
Hemolyses And Related Conditions	8 (.57%)
Mental Impairment	8 (.57%)
Water, Electrolyte And Mineral	8 (.57%)
Administration Site Reactions	7 (.5%)
Enzyme	7 (.5%)
Gastrointestinal	7 (.5%)
Gastrointestinal Stenosis And Obstr...	7 (.5%)
Injuries	7 (.5%)
Upper Respiratory Tract Disorders	7 (.5%)
Viral Infectious	7 (.5%)
Hematological And Lymphoid Tissue T...	6 (.43%)
Procedural And Device Related Injur...	6 (.43%)
Purine And Pyrimidine Metabolism	6 (.43%)
Bacterial Infectious	5 (.36%)
Disturbances In Thinking	5 (.36%)
Increased Intracranial Pressure And...	5 (.36%)
Vision	5 (.36%)
Allergic Conditions	4 (.28%)
Appetite And General Nutritional	4 (.28%)
Central Nervous System Vascular	4 (.28%)
Chemical Injury And Poisoning	4 (.28%)
Skin Appendage Conditions	4 (.28%)
Abdominal Hernias And Other Abdomin...	3 (.21%)
Anal And Rectal Conditions	3 (.21%)
Arteriosclerosis, Stenosis, Vascula...	3 (.21%)
Lipid Metabolism	3 (.21%)
Myocardial	3 (.21%)
Pleural	3 (.21%)
Protein And Chemistry Analyses	3 (.21%)
Seizures	3 (.21%)
Therapeutic Procedures And Supporti...	3 (.21%)
Tissue	3 (.21%)
Toxicology And Therapeutic Drug Mon...	3 (.21%)
Cardiac Disorder Signs	2 (.14%)
Cardiac Valve	2 (.14%)
Changes In Physical Activity	2 (.14%)
Dental And Gingival Conditions	2 (.14%)
Endocrine Investigations	2 (.14%)
Gastrointestinal Neoplasms Malignan...	2 (.14%)
Gastrointestinal Therapeutic Proced...	2 (.14%)
Immunology And Allergy	2 (.14%)
Investigations, Imaging And Histopa...	2 (.14%)
Metastases	2 (.14%)
Microbiology And Serology	2 (.14%)
Musculoskeletal And Connective Tiss...	2 (.14%)
Neuromuscular	2 (.14%)
Pericardial	2 (.14%)
Peritoneal And Retroperitoneal Cond...	2 (.14%)
Product Quality Issues	2 (.14%)
Protein And Amino Acid Metabolism	2 (.14%)
Protozoal Infectious	2 (.14%)
Skin And Subcutaneous Tissue	2 (.14%)
Spleen, Lymphatic And Reticulendoth...	2 (.14%)
Tongue Conditions	2 (.14%)
Vascular Hypertensive	2 (.14%)
Vascular Inflammations	2 (.14%)
Anxiety Disorders	1 (.07%)
Bladder And Bladder Neck Disorders	1 (.07%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Repaglinide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Repaglinide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.